Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135173 | 0.86 | PTK2 (0.76) | PTK2MAPK8MAPK10MAPTNPC1 | |
| SCHEMBL10202041 | 0.85 | PTK2 (0.73) | PTK2MAPK8MAPK10MAPTNPC1 | |
| SCHEMBL1680689 | 0.85 | PTK2 (0.73) | PTK2MAPK8MAPK10MAPTNPC1 | |
| SCHEMBL1704195 | 0.83 | PTK2 (0.71) | PTK2MAPK8MAPK10MAPTALDH1A1 | |
| SCHEMBL11946878 | 0.83 | PTK2 (0.71) | PTK2MAPK8MAPK10MAPTNPC1 | |
| SCHEMBL13270043 | 0.83 | PTK2 (0.71) | PTK2MAPK8MAPK10MAPTNPC1 | |
| SCHEMBL24488916 | 0.82 | PTK2 (0.70) | PTK2MAPK8MAPK10MAPTNPC1 | |
| SCHEMBL7056886 | 0.82 | PTK2 (0.70) | PTK2MAPK8MAPK10MAPTNPC1 | |
| SCHEMBL23323409 | 0.81 | PTK2 (0.69) | PTK2MAPK8MAPK10MAPTNPC1 | |
| SCHEMBL19494280 | 0.81 | PTK2 (0.68) | PTK2MAPK8MAPK10MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867806-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-01-16 | — | — | US | disclosed |
| US-9867806-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-01-16 | — | — | US | disclosed |
| US-9867806-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-01-16 | — | — | US | disclosed |
| EP-2994463-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2017-10-25 | — | — | EP | disclosed |
| EP-2994463-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2017-10-25 | — | — | EP | disclosed |
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2016-09-15 | — | — | US | disclosed |
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2016-09-15 | — | — | US | disclosed |
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2016-09-15 | — | — | US | disclosed |
| US-9382254-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-07-05 | — | — | US | disclosed |
| US-9382254-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-07-05 | — | — | US | disclosed |
| US-7375131-B2 | NF-κB inhibitors | SMITHKLINEBEECHAM CORP. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1532133-A4 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060030596-A1 | NF-kappaB inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-02-09 | — | — | US | disclosed |
| US-20050165087-A1 | For treating diseases with aminothiophene inhibitors of IKK-beta phosphorylation of I kappa B, including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease | CALLAHAN JAMES F (US) | 2005-07-28 | — | — | US | disclosed |
| EP-1532133-A1 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1324759-A4 | NF-G(K)B INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040024047-A1 | Nf-kb inhibitors | SMITHKLINE BEECHMAN CORPORATION | 2004-02-05 | — | — | US | disclosed |
| WO-2003104218-A1 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| EP-1324759-A2 | NF-G(K)B INHIBITORS | SmithKline Beecham Corporation (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030353-A2 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC3, ABCC5 | PTK2 3198/4885MAPK8 4691/4885MAPK10 4123/4885 |
| US-20050165087-A1 | For treating diseases with aminothiophene inhibitors of IKK-beta phosphorylation of I kappa B, including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease | NFKBIA, IKBKG, IKBKE | PTK2 180/4885MAPK8 2048/4885MAPK10 792/4885 |
| US-20060030596-A1 | NF-kappaB inhibitors | NFKBIA, IKBKB, IKBKG | PTK2 805/4885MAPK8 1820/4885MAPK10 716/4885 |
| US-20040024047-A1 | Nf-kb inhibitors | NFKBIA, IKBKB, IKBKG | PTK2 481/4885MAPK8 1153/4885MAPK10 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.